Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06667414 · ClinicalTrials.gov registry record
Frequency of Selected Single Nucleotide Polymorphisms in Huntington Disease Gene Expansion Carriers
A clinical trial of Huntington Disease, sponsored by Hoffmann-La Roche.
- Recruiting
- Registry status
- 600
- Enrollment target
- 20
- Study locations
NCT06667414: Recruiting study of Huntington Disease, sponsored by Hoffmann-La Roche.
NCT06667414 is a study of Huntington Disease that is actively recruiting participants, run by Hoffmann-La Roche. The registered enrollment target is 600 participants, roughly in line with the 618-participant average among 35 other Huntington Disease trials with a reported enrollment target. The trial reports 20 study locations across 18 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06667414, a study of Huntington Disease, is actively recruiting participants, sponsored by Hoffmann-La Roche.
- RECRUITING
- Registry status
- 600 participants
- Enrollment target
- 20
- Study locations
Study Summary
For participation in this epidemiological study, a single-day visit at the study site is required. Participants will be recruited from Huntington Disease clinics, and they will be asked to answer questions regarding their demographics, including sex, age, race and ethnicity, and their medical and medication history. At the end of the visit, a blood sample will be drawn to allow testing with a sequencing assay that is specifically designed for phasing single nucleotide polymorphisms (SNPs) on the wild-type Huntington (wtHTT) and mutant Huntington (mHTT) alleles.
Conditions Studied
Study Locations (20)
California
- University of California San Diego - La Jolla
- University of California Davis Medical System - Sacramento
New South Wales
- Calvary Health Care Bethlehem - Caulfield South
- Westmead Hospital - Westmead
Alabama
- Uab Medicine - Birmingham
Arizona
- Barrow Neurological Institute - Phoenix
Colorado
- CenExel Rocky Mountain Clinical Research, LLC - Englewood
Florida
- University of South Florida - Tampa
Illinois
- Northwestern University - Chicago
Iowa
- University of Iowa Hospitals and Clinics - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2024-09-02 |
| Est. Completion | 2028-09-24 |
What NCT06667414 shows while recruiting
NCT06667414 is an observational study that tracks outcomes without assigning an intervention. The registered 600 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 618-participant average among 35 other Huntington Disease trials with a reported enrollment target.
The record links to 1 condition, with Huntington Disease appearing as the primary indexed condition, and to 0 interventions.
NCT06667414 names 20 study sites across 18 states, led by California, New South Wales, Alabama.
Frequently Asked Questions
What is clinical trial NCT06667414 about?
NCT06667414 is a clinical study titled "Frequency of Selected Single Nucleotide Polymorphisms in Huntington Disease Gene Expansion Carriers". For participation in this epidemiological study, a single-day visit at the study site is required. Participants will be recruited from Huntington Disease clinics, and they will be asked to answer questions regarding their demographics, including sex, age, race and ethnicity, and their medical and me...
What is the current status of trial NCT06667414?
This trial is currently recruiting. The enrollment target is 600 participants. The study started on 2024-09-02. Estimated completion is 2028-09-24.
What conditions does trial NCT06667414 study?
This clinical trial studies the following conditions: Huntington Disease.
Who is sponsoring clinical trial NCT06667414?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06667414 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Huntington Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06667414's enrollment target sits among peer trials
600 8th of 35 higher than 27 of 35 other Huntington Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Huntington Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Modification of Threat Interpretation Bias to Reduce Anxiety in Neurodegenerative Movement Disorders (Aim 3)
RECRUITING · NA
-
Longitudinal Endpoint Assessment of Disease Burden in HD
RECRUITING
-
Extracellular Vesicles for HD
RECRUITING
-
A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease
RECRUITING · Phase 3
-
A Randomized Study of SPK-10001 Gene Therapy in Participants With Huntington's Disease
RECRUITING · Phase 1
-
Gut Microbiomes in HD
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004317 · 600 participants · Phase 4
Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis
- NCT00209235 · 600 participants · NA
Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments
- NCT01473784 · 600 participants · NA
Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck
- NCT01866371 · 600 participants
High Resolution Retinal Imaging
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI